/
DCF Valuation
Base-case fair value
$17.31
Intrinsic $23.08 · 25% MOS
Current price: $81.75
Base-case summary
Our base-case DCF for Corcept Therapeutics Inc (CORT) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $120M in trailing free cash flow, this produces an intrinsic value of $23.08 per share. A 25% safety margin gives a fair value of $17.31, suggesting the stock is currently 79% overvalued against the $81.75 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$120M
Cash & equivalents
$338M
Total debt
$10M
Shares outstanding
104M